ClinicalTrials.gg
CompletedNCT01992380Updated Sep 7, 2020Results posted

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-07.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
16th of 22
24 · median 70
Started
2013
with 2 others
Phase 1
10 of 22
2 open now
Registered
1st of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 16th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 1, and was the 1st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteers

    • Male or female subjects ≥ 50 years of age
    • (MMSE) ≥ 29
  • MCI Subjects

    • Male or female subjects ≥ 50 years of age
    • MMSE ≥ 24
    • Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD
    • Have a study partner that can report on subject's activities of daily living
  • Probable AD Subjects

    • Male or female subjects ≥ 50 years of age
    • MMSE > 10
    • Meet clinical criteria for probable AD based on the NIA-AA working group's diagnostic guidelines for AD
    • Have a study partner that can report on subject's activities of daily living

Exclusion criteria

Exclusion Criteria:

  • Current psychiatric disease
  • Evidence of structural brain abnormalities
  • Evidence of dementing illness other than AD
  • Current clinically significant cardiovascular disease or abnormalities, or additional risk factors for Torsades de Pointes
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • History of alcohol or substance abuse or dependence
  • Females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have received or participated in a trial with medications in the past 30 days
  • have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Healthy Volunteer Subjects

    Healthy males or females 50 years or older with no evidence of cognitive impairment

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    MCI subjects

    Subjects 50 years or older with mild cognitive impairment (MCI)

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Probable AD Subjects

    Subjects 50 years or older with probable Alzheimer's Disease (AD)

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • IV injection, 370 MBq (10 mCi), two doses up to four weeks apart

    Also known as: [F18]T807, 18F-AV-1451, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection

06

What researchers measure

Primary outcomes

  1. Test-Retest Reproducibility

    Evaluate test-retest reproducibility of flortaucipir for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects

    Time frame: 80-100 minutes postdose

  2. Test-Retest Reproducibility

    Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects

    Time frame: 110-130 minutes postdose

07

Results

Posted Sep 7, 2020

Participant flow

Enrollment between Nov 2013 and May 2014

Participant flow — Overall Study
MilestoneHealthy Volunteer SubjectsMCI SubjectsProbable AD Subjects
Started6810
Completed6810
Not completed000

Outcome measures

PrimaryTest-Retest Reproducibility

Evaluate test-retest reproducibility of flortaucipir for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects

Time frame:
80-100 minutes postdose
Reported as:
Mean · standardized uptake value ratio (SUVr)
Test-Retest Reproducibility
standardized uptake value ratio (SUVr)All Subjects
Test Imaging1.342 ± 0.341
Retest Imaging1.355 ± 0.309
Statistical analysis
  • All Subjects · Icc: 0.971 · 95% CI 0.935 to 0.988Assessed the agreement between the test and retest imaging of the combination VOI SUVr
PrimaryTest-Retest Reproducibility

Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects

Time frame:
110-130 minutes postdose
Reported as:
Mean · standardized uptake value ratio (SUVr)
Test-Retest Reproducibility
standardized uptake value ratio (SUVr)All Subjects
Test Imaging1.459 ± 0.455
Retest Imaging1.457 ± 0.396
Statistical analysis
  • All Subjects · Icc: 0.968 · 95% CI 0.926 to 0.986Assessed the agreement between the test and retest imaging of the combination VOI SUVr

Adverse events

Collected over End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Non-serious events are listed at a 1.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteer Subjects0/6 (0%)0/6 (0%)1/6 (16.7%)
MCI Subjects0/8 (0%)0/8 (0%)0/8 (0%)
Probable AD Subjects0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventHealthy Volunteer SubjectsMCI SubjectsProbable AD Subjects
hypertensionVascular disorders0/60/82/10
dysgeusiaNervous system disorders1/60/80/10
diarrhoeaGastrointestinal disorders0/60/81/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
Mean62.8 ± 9.570.3 ± 5.474.4 ± 7.370.1 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
Female4228
Male26816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
Hispanic or Latino0000
Not Hispanic or Latino681024
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White581023
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
United States681024
Mini Mental Status Exam (MMSE)
Mini Mental Status Exam (MMSE)(units on a scale)Healthy Volunteer SubjectsMCI SubjectsProbable AD SubjectsTotal
Mean29.7 ± 0.5228.3 ± 1.5823.9 ± 4.5826.8 ± 3.95
08

Study locations

2 sites
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    New Haven, Connecticut 06510, United States
09

References and documents

Publications

  • Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, Mintun MA. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. J Nucl Med. 2018 Jun;59(6):937-943. doi: 10.2967/jnumed.117.200691. Epub 2017 Dec 28. PubMed 29284675 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in May 2014, 6 months.

Results were first posted in Sep 2020, 6 years 3 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 6 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 25, 2013
StartActual
Nov 13, 2013
Primary completionActual
May 30, 2014
CompletionActual
May 30, 2014
Results first posted
Sep 7, 2020
Last update
Sep 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01992380
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Nov 13, 2013
Primary completion
May 30, 2014
Completion
May 30, 2014
Results posted
Sep 7, 2020
Last update
Sep 7, 2020

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion